Tianjin TEDA Biomedical Engineering Company Limited
Symboli: 8189.HK
HKSE
0.068
HKDMarkkinahinta tänään
-5.3122
P/E-suhde
-0.1354
PEG-suhde
148.68M
MRK Cap
- 0.00%
DIV Tuotto
Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 78.81 | 5.9 | 9.5 | 29.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 129.84 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.net-receivables | 29.14 | 8.8 | 31.9 | 32.1 | |||||||||||||||||||
balance-sheet.row.inventory | 188.07 | 90.5 | 74 | 75.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 97.68 | 85.2 | 80.3 | 75 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 442.5 | 190.3 | 193.1 | 208.7 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 227.33 | 99.7 | 118.5 | 125 | |||||||||||||||||||
balance-sheet.row.goodwill | 5.53 | 0 | 5.5 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 18.94 | 13.3 | 20.1 | 13.9 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 24.47 | 13.3 | 25.6 | 13.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -203.31 | 0 | -144.1 | -138.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 187.35 | 112.9 | 144.1 | 138.8 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 629.86 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 26.08 | 16.1 | 20.7 | 29.5 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 124.04 | 63.3 | 60.8 | 45.1 | |||||||||||||||||||
balance-sheet.row.tax-payables | 2.34 | 0 | 3.1 | 1.5 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.53 | 20.3 | 35.2 | 45.2 | |||||||||||||||||||
Deferred Revenue Non Current | -1.56 | -1.6 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.56 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 164.22 | 13.4 | 136.7 | 117.4 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 57.09 | 21.9 | 35.2 | 45.2 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 51.09 | 11.9 | 39.2 | 42.9 | |||||||||||||||||||
balance-sheet.row.total-liab | 495.52 | 238.7 | 253.5 | 237.2 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 131.74 | 3.7 | 16.8 | 16.8 | |||||||||||||||||||
balance-sheet.row.common-stock | 378.9 | 189.4 | 189.4 | 189.4 | |||||||||||||||||||
balance-sheet.row.retained-earnings | -791.91 | -401.7 | -379 | -350.9 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -10.77 | -16.8 | -16.8 | -16.8 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 556.88 | 275.3 | 262.2 | 262.2 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 264.85 | 50 | 72.7 | 100.8 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.33 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 22.96 | 14.6 | 11 | 9.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 287.81 | 64.6 | 83.7 | 110.4 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.33 | - | - | - | |||||||||||||||||||
Total Investments | 129.84 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.total-debt | 179.57 | 83.6 | 96 | 90.3 | |||||||||||||||||||
balance-sheet.row.net-debt | 230.6 | 77.6 | 89.2 | 63.9 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.16 | -26.5 | -44.8 | -50 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 15.4 | 9.5 | 7.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1.7 | -5.3 | 43.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | -2.1 | 0.1 | -4.3 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 1.2 | 16.4 | -2.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.1 | -0.1 | 4.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -3 | -21.8 | 46.2 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 20.16 | 0 | 34 | 35.4 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2.17 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.46 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6.4 | 1.1 | 1.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -22.8 | -22 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0.7 | 43.8 | -1.9 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1.5 | 3 | 10.3 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -1.46 | -12.9 | -8.5 | -26.5 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -46.8 | -16 | -31.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 53 | 44.1 | 11 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6.2 | 28.1 | -20.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0.38 | -19.6 | 12.9 | -10.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 8.07 | 6.9 | 26.4 | 13.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7.7 | 26.4 | 13.5 | 24.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 2.17 | -12.8 | -6.7 | 36 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -1.46 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0.71 | -21.6 | -40.4 | 22 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 398 | 398 | 449.7 | 476.4 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 376.63 | 376.6 | 433.3 | 430.8 | |||||||||||||||||||
income-statement-row.row.gross-profit | 21.37 | 21.4 | 16.4 | 45.6 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 1.32 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 9.74 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 8.1 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -0.32 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 31.2 | 31.2 | 38.5 | 51.8 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 407.83 | 407.8 | 471.8 | 482.5 | |||||||||||||||||||
income-statement-row.row.interest-income | 4.92 | 0.2 | 0.8 | 0.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 5.17 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 8.1 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.96 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -0.32 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 5.96 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 5.17 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.37 | 11.6 | 15.4 | 9.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | -9.9 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | -17.97 | -19.3 | -20.8 | -4.4 | |||||||||||||||||||
income-statement-row.row.income-before-tax | -12.01 | -12 | -26.5 | -44.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | -0.86 | -1 | 0.2 | -0.1 | |||||||||||||||||||
income-statement-row.row.net-income | -21.99 | -20.2 | -26.6 | -44.8 |
Usein kysytty kysymys
Mikä on Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) taseen loppusumma?
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) kokonaisvarat ovat 303277966.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 212082169.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.054.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 0.000.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.055.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.045.
Mikä on Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -20159658.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 83557328.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 31200528.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 5934322.000.